

# Association of a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13 polymorphisms with severity of coronary stenosis in type 2 diabetes mellitus

Supakanya Lasom<sup>1,2</sup>, Nantarat Komanasin<sup>2,3</sup>, Nongnuch Settasatian<sup>2,4</sup>, Chatri Settasatian<sup>2,5</sup>, Upa Kukongviriyapan<sup>2,6</sup>, Pongsak Intharapetch<sup>2,7</sup>

<sup>1</sup>Biomedical Science Program, Graduate School, Khon Kaen University, <sup>2</sup>Cardiovascular Research Group, Khon Kaen University, Departments of <sup>3</sup>Clinical Microscopy and <sup>4</sup>Clinical Chemistry, Faculty of Associated Medical Sciences, Khon Kaen University, Departments of <sup>5</sup>Pathology and <sup>6</sup>Physiology, Faculty of Medicine, Khon Kaen University, <sup>7</sup>Queen Sirikit Heart Center of the Northeast, Khon Kaen University, Khon Kaen, Thailand

**Background:** The imbalance of von Willebrand factor (vWF) and a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13 (ADAMTS13) has been associated with atherosclerosis progression. A high level of vWF which regulates thrombus formation is associated with diabetes mellitus (DM), and some *ADAMTS13* and *vWF* polymorphisms have effects on their levels. Therefore, this study aimed to evaluate the associations of *ADAMTS13* and *vWF* polymorphisms and their levels with DM and severity of coronary stenosis. **Materials and Methods:** Eighty-seven DM and 84 control individuals were recruited. vWF and ADAMTS13 activities as well as vWF antigen were measured by collagen-binding assay (CBA), residual-CBA, and in-house enzyme-linked immunosorbent assay, respectively. *ADAMTS13* and *vWF* polymorphisms were determined by polymerase chain reaction-restriction fragment length polymorphism. **Results:** The E and G alleles and AA genotype of *ADAMTS13* Q448E, rs2073932, and rs652600, respectively, were independently associated with DM (odds ratio [OR] [95% confidence interval (CI)] = 2.5 [1.1, 5.6], 2.3 [1.0, 5.2], and 4.7 [1.2, 18.6], respectively). Moreover, E allele and AA genotype of Q448E and rs652600 were also significantly associated with multi-vessel disease (OR [95% CI] = 2.2 [1.0, 4.8] and 3.2 [1.0, 10.0], respectively), while the E and G allele of Q448E and rs2073932 were associated with high Gensini score (OR [95% CI] = 2.3 [1.1, 4.9] and 2.3 [1.1, 5.1], respectively). **Conclusion:** Association of *ADAMTS13* polymorphisms with DM, number of vessel stenosis, and Gensini score may indicate the possible contribution of *ADAMTS13* polymorphisms to atherosclerosis progression and severity of coronary stenosis in DM.

**Key words:** A disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13, coronary stenosis, diabetes mellitus, polymorphism

**How to cite this article:** Lasom S, Komanasin N, Settasatian N, Settasatian C, Kukongviriyapan U, Intharapetch P. Association of a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13 polymorphisms with severity of coronary stenosis in type 2 diabetes mellitus. *J Res Med Sci* 2018;23:59.

## INTRODUCTION

Diabetes mellitus (DM) is a major risk factor for coronary artery disease (CAD). It has been known that cardiovascular disease (CVD) is the most important complication and approximately 75% of type 2 diabetic patients die from CVD.<sup>[1]</sup> This observation can be

explained by several mechanisms including concomitant risk factors such as hypertension, dyslipidemia, hyperglycemia, obesity, and metabolic syndrome which are responsible for endothelial dysfunction.<sup>[2]</sup> Recently, many studies have suggested that proteins or factors relating to endothelial dysfunction were considered to be associated with DM.<sup>[3]</sup> von Willebrand factor (vWF) is an important biomarker of endothelial dysfunction. It plays

### Access this article online

Quick Response Code:



Website:  
[www.jmsjournal.net](http://www.jmsjournal.net)

DOI:  
10.4103/jrms.JRMS\_518\_17

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

**For reprints contact:** [reprints@medknow.com](mailto:reprints@medknow.com)

**Address for correspondence:** Dr. Nantarat Komanasin, Department of Clinical Microscopy, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand. E-mail: [nankom@kku.ac.th](mailto:nankom@kku.ac.th)

**Received:** 21-06-2017; **Revised:** 21-11-2017; **Accepted:** 18-03-2018

a crucial role in primary hemostasis and thrombus formation by mediating platelet adhesion and aggregation. Upon released from endothelial cells, ultralarge vWF multimers which are the most thrombogenic are cleaved into the less active forms by a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13 (ADAMTS13).<sup>[4]</sup> Reduction in ADAMTS13 activity and elevated vWF antigen are associated with thrombotic thrombocytopenic purpura<sup>[4]</sup> and other thrombotic diseases such as ischemic stroke,<sup>[5]</sup> acute myocardial infarction,<sup>[6]</sup> and CAD.<sup>[7]</sup>

High-circulating vWF concentrations are known to be associated with DM,<sup>[8,9]</sup> which mainly caused by endothelial dysfunction. It has been found to be a link to the development of microvascular and macrovascular diseases<sup>[9,10]</sup> and a risk marker for death in diabetic patients.<sup>[11]</sup> On the other hand, there are few studies reporting ADAMTS13 levels in DM and the results were inconsistent. Skeppholm *et al.*<sup>[8]</sup> have suggested that ADAMTS13 activity was significantly lower in diabetic patients and a decrease in ADAMTS13 activity was also associated with an increased risk of cardiovascular events and renal disease in type 2 DM patients.<sup>[12]</sup> In contrast, the recent study has demonstrated that ADAMTS13 activity was elevated in type 1 DM patients with retinopathy.<sup>[10]</sup> Although vWF is released from endothelial cells, increased circulating vWF may not only due to elevated endothelial secretion or endothelial damage but may also partly be related to a reduction of ADAMTS13 function. Many ADAMTS13 and vWF polymorphisms have been reported to be associated with impaired ADAMTS13 activity as well as increased vWF antigen and activity.<sup>[13-15]</sup> Thus, vWF and ADAMTS13 genes may have an important role in genetic susceptibility to the thrombotic development or vascular complication in DM.

So far, there is no study investigating the possible relationship of known ADAMTS13 and vWF polymorphisms with DM and the progression of the plaque in coronary artery of the patients with macrovascular complication. In addition, the association between ADAMTS13 and DM is controversy. Therefore, those associations were explored in this study. Genetic variations of ADAMTS13 and vWF associated with impaired ADAMTS13 activity and increased levels of vWF antigen and activity were selected as the candidate polymorphisms. The polymorphisms were investigated in type 2 DM patients with CAD complication. This genetic association study could possibly provide the new insights into the role of ADAMTS13 and vWF polymorphisms in thrombus formation and vascular complication of DM in Thai population.

## MATERIALS AND METHODS

### Subjects

A total of 171 participants who attended to the Cardiac Catheterization Unit, Queen Sirikit Heart Center of

the Northeast Hospital, Khon Kaen University, for cardiovascular checkup (2008–2010) were recruited in this study. Patients with acute coronary syndrome, left ventricular hypertrophy, heart failure, cardiomyopathy, valvular heart disease, deep vein thrombosis, liver disease, renal disease, and inflammatory disease were excluded. Type 2 DM was diagnosed according to the criteria of the World Health Organization.<sup>[16]</sup> According to the coronary angiographic results, the DM participants ( $n = 87$ ) were diagnosed as CAD if the angiographic results of coronary arteries showing  $\geq 50\%$  stenosis (single-vessel disease or multi-vessel disease). The individuals without DM and presenting none or  $< 50\%$  stenosis were classified as control group ( $n = 84$ ). The severity of coronary stenosis was determined using the numbers of main vessel stenosis  $\geq 50\%$  together with Gensini score, which was calculated from the degree of luminal narrowing and its geographic importance of coronary artery.<sup>[17]</sup> Patients with Gensini score  $\geq 20$  were classified as high score, while those presenting the score  $< 20$  were defined as low–medium score.<sup>[18]</sup> Other clinical variables including age, sex, CAD risk factors, and use of medicines were obtained from medical records. Individuals presenting one or more of the following parameters: total cholesterol (TC)  $\geq 6.2$  mmol/L, triglyceride  $\geq 2.3$  mmol/L, high-density lipoprotein-cholesterol (HDL-C)  $< 1.0$  mmol/L, and low-density lipoprotein-cholesterol (LDL-C)  $\geq 4.1$  mmol/L or use of lipid-lowering drugs were diagnosed as dyslipidemia.<sup>[19]</sup> Individuals whom had blood pressure  $\geq 140/90$  mmHg and/or used anti-hypertensive drugs were defined as hypertension.<sup>[20]</sup> Individuals with body mass index (BMI)  $\geq 25$  kg/m<sup>2</sup> were classified as obesity.<sup>[21]</sup> Metabolic syndrome was considered if any three in five risk factors were presented: (i) waist circumference  $> 90$  cm in male and  $> 80$  cm in female, (ii) TG  $> 1.7$  mmol/L or on lipid-lowering drug treatment, (iii) HDL-C  $< 1.0$  mmol/L in male and  $< 1.3$  mmol/L in female, (iv) blood pressure  $> 130/85$  mmHg or use of anti-hypertensive medications, and (v) fasting blood glucose (FBG)  $> 5.6$  mmol/L or use of glucose-lowering drugs.<sup>[22]</sup> The study was approved by the Khon Kaen University Ethics Committee for Human Research (HE510414). Signed consent form was obtained from each participant after explanation of the study.

### Laboratory measurements

Blood samples were obtained after 12 h of fasting before undergoing coronary angiography. Four milliliters of blood samples was collected in 3.2% tri-sodium citrate and immediately placed on ice. Platelet poor plasma was further separated within 30 min by centrifugation at 1500 g at 4°C for 15 min. All plasma samples were stored in small aliquots at  $-80^{\circ}\text{C}$  until use. vWF antigen and activity were measured by an in-house sandwich enzyme-linked immunosorbent assay and collagen-binding assay (CBA), respectively,

while ADAMTS13 activity was determined by residual CBA as previously described.<sup>[14]</sup> The other blood chemical analysis serum high-sensitivity C-reactive protein (hs-CRP) concentration was examined by immunonephelometry using BN ProSpec® System (Siemens Healthcare Diagnostics Products GmbH, Germany).

### Polymorphism analysis

Genotyping of *ADAMTS13* and *vWF* polymorphisms including *ADAMTS13* Q448E (rs2301612), rs2073932, rs652600, rs4962153, and *vWF* V1565 L (rs1800385) was performed by polymerase chain reaction-restriction fragment length polymorphism technique as described in the previous study.<sup>[14]</sup>

### Statistical analysis

Statistical analysis was performed using the SPSS version 17.0 (SPSS Inc., IL, USA). Kolmogorov–Smirnov was applied to test whether data were normally distributed. The continuous values were expressed as mean ± standard deviation (SD). If the values were not normal distribution, they were transformed to logarithm before comparison and presented as geometric mean ± SD. Independent sample *t*-test and one-way analysis of variance were used to compare continuous values between two or more than two groups, respectively. The  $\chi^2$ -test was performed for comparison of categorical variables such as CAD risk factors and genotype frequencies. The Hardy–Weinberg equilibrium was evaluated by  $\chi^2$ -test, and all genotype distributions observed in this study were compatible with Hardy–Weinberg equilibrium. Jonckheere–Terpstra test was used to analyze the probability of trend for a continuous variable across an ordinal group. Multivariate logistic regression analysis was performed to evaluate the association of genotypes with DM and severity of coronary stenosis. Statistical significance was considered when  $P < 0.05$ .

## RESULTS

Individuals in DM group presented higher proportions of hypertension, metabolic syndrome, as well as Gensini score, systolic blood pressure, triglyceride, FBG, insulin levels, homeostasis model assessment of insulin resistance (HOMA-IR), and white blood cell count as compared to controls. No significant differences between both groups were observed for BMI, TC, LDL-C, hs-CRP levels, and number of white blood cells [Table 1]. *vWF* antigen was likely to increase in DM compared to control group ( $94.5 \pm 40.4$  [ $n = 87$ ] vs.  $83.1 \pm 39.6$  IU/dL [ $n = 84$ ],  $P$  for trend = 0.032). However, no significant differences of *ADAMTS13* activity ( $72.3 \pm 18.1$  [ $n = 87$ ] vs.  $73.1 \pm 17.9\%$  [ $n = 84$ ],  $P = 0.775$ ), *vWF* activity ( $99.6 \pm 28.8$  [ $n = 87$ ] vs.  $94.7 \pm 25.7$  IU/dL [ $n = 84$ ],  $P = 0.249$ ), and *vWF* antigen/*ADAMTS13* activity

**Table 1: Baseline characteristics of the study subjects**

Parameters	DM (n=87)	Control (n=84)	P
Age (years)	62.0±8.5	60.0±9.7	0.151
Male, n (%)	46 (52.9)	39 (46.4)	0.399
Metabolic syndrome, n (%)	79 (92.9)	35 (47.9)	<0.001
Hypertension, n (%)	75 (86.2)	55 (65.5)	0.002
Dyslipidemia, n (%)	82 (95.3)	74 (88.1)	0.085
Obesity, n (%)	41 (47.7)	37 (44.0)	0.635
Smoking, n (%)	25 (28.7)	21 (25.0)	0.582
Gensini score	25.6±2.9	0.5±1.4	<0.001
BMI (kg/m <sup>2</sup> )	25.2±3.2	25.0±3.5	0.742
SBP (mmHg)	134.7±19.7	126.7±17.3	0.006
DBP (mmHg)	74.6±10.6	73.4±9.5	0.464
Total cholesterol (mmol/L)	4.6±1.5	4.4±0.1	0.244
Triglycerides (mmol/L)*	1.9±0.1	1.5±0.1	0.010
HDL-C (mmol/L)*	1.0±0.1	1.1±0.1	0.017
LDL-C (mmol/L)	2.6±1.0	2.4±1.0	0.320
FBG (mmol/L)*	7.9±0.1	5.1±0.1	<0.001
Insulin (μIU/mL)*	18.3±1.6	14.9±1.5	0.002
HOMA-IR*	6.5±1.9	3.4±1.6	<0.001
hs-CRP (mg/L)*	1.9±2.8	1.6±3.5	0.455
White blood cell count (10 <sup>3</sup> /μL)	7.5±2.2	6.8±1.6	0.015
Drug medication			
Metformin, n (%)	40 (46.0)	0	<0.001
Statin, n (%)	71 (81.6)	63 (75.0)	0.294
Nitrate, n (%)	73 (83.9)	63 (75.0)	0.149
ACE inhibitor	32 (36.8)	19 (22.6)	0.043
Plavix	44 (50.6)	18 (21.4)	<0.001
Aspirin	80 (92.0)	71 (84.5)	0.131

Independent sample *t*-test and Chi-square test were used to compare continuous values and categorical variables between both groups, respectively. The continuous values are expressed as mean±SD. Frequency is presented as *n* and percentage. \*Values are presented as geometric mean±SD. DM=Diabetes mellitus; SBP=Systolic blood pressure; DBP=Diastolic blood pressure; HDL-C=High-density lipoprotein cholesterol; LDL-C=Low-density lipoprotein cholesterol; FBG=Fasting blood glucose; HOMA-IR=Homeostasis model assessment of insulin resistance; hs-CRP=High sensitivity C-reactive protein; SD=Standard deviation; ACE=Angiotensin-converting enzyme; BMI=Body mass index

ratio ( $1.2 \pm 1.0$  [ $n = 87$ ] vs.  $1.0 \pm 0.6$  [ $n = 84$ ],  $P = 0.113$ ) were observed between both groups.

Frequencies of QE genotype and E allele carrier of *ADAMTS13* Q448E, AG genotype and G allele carrier of *ADAMTS13* rs2073932, as well as AA genotype of *ADAMTS13* rs652600 were significantly higher in DM individuals than those in control group ( $P < 0.05$ ) [Table 2]. To evaluate the association of genetic variations with DM, multivariate logistic regression analysis was performed. The results demonstrated that presences of QE genotype and E allele carrier of the Q448E, AG genotype and G allele carrier of the rs2073932, as well as AA genotypes of the rs652600 were found to be independently associated with DM after adjustment for gender, age, hypertension, and metabolic syndrome [Table 2].

To classify the severity of coronary stenosis in DM individuals with CAD, the number of stenotic vessels and Gensini score

**Table 2: Prevalence of a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13 and von Willebrand factor polymorphisms and their associations with diabetes mellitus**

Polymorphism	Genotype frequency		OR (95% CI)		
	DM (n=87), n (%)	Control (n=84), n (%)	Crude OR	Adjusted OR*	Adjusted OR†
<i>ADAMTS13</i> gene					
Q448E					
QQ	29 (33.3)	43 (51.2)	1.0	1.0	1.0
QE	45 (51.7) <sup>‡</sup>	34 (40.5)	2.0 (1.0-3.8) <sup>§</sup>	2.0 (1.0-3.8) <sup>§</sup>	2.4 (1.0-5.5) <sup>§</sup>
EE	13 (14.9)	7 (8.3)	2.8 (1.0-7.7)	2.7 (0.9-7.7)	3.8 (0.9-15.3)
E allele	58 (66.7) <sup>‡</sup>	41 (48.8)	2.1 (1.1-3.9) <sup>§</sup>	2.1 (1.1-3.9) <sup>§</sup>	2.5 (1.1-5.6) <sup>§</sup>
rs2073932					
AA	27 (31.0)	41 (48.8)	1.0	1.0	1.0
AG	47 (54.0) <sup>‡</sup>	34 (40.5)	2.1 (1.1-4.0) <sup>§</sup>	2.1 (1.1-4.2) <sup>§</sup>	2.6 (1.1-6.1) <sup>§</sup>
GG	13 (14.9)	9 (10.7)	2.2 (0.8-5.8)	2.2 (0.8-6.0)	2.3 (0.7-8.2)
G allele	60 (69.0) <sup>‡</sup>	43 (51.2)	2.1 (1.1-4.0) <sup>§</sup>	2.1 (1.1-4.0) <sup>§</sup>	2.3 (1.0-5.2) <sup>§</sup>
Rs652600					
GG	26 (29.9)	37 (44.0)	1.0	1.0	1.0
GA	43 (49.4)	37 (44.0)	1.7 (0.9-3.2)	1.7 (0.9-3.3)	1.8 (0.8-4.2)
AA	18 (20.7) <sup>‡</sup>	10 (11.9)	2.6 (1.0-6.4) <sup>§</sup>	2.8 (1.1-7.1) <sup>§</sup>	4.7 (1.2-18.6) <sup>§</sup>
A allele	61 (70.1)	47 (56.0)	1.9 (1.0-3.5)	1.9 (1.0-3.6)	2.1 (0.9-4.8)
rs4962153					
GG	68 (78.2)	65 (77.4)	1.0	1.0	1.0
GA	18 (20.7)	15 (17.9)	1.2 (0.5-2.5)	1.1 (0.5-2.4)	1.6 (0.6-4.6)
AA	1 (1.1)	4 (4.8)	0.2 (0.0-2.2)	-	-
A allele	19 (21.8)	19 (22.6)	1.0 (0.5-2.0)	0.9 (0.4-1.9)	1.3 (0.5-3.6)
<i>vWF</i> gene					
V1565L					
VV	75 (86.2)	66 (78.6)	1.0	1.0	1.0
VL	11 (12.6)	17 (20.2)	0.6 (0.2-1.3)	0.6 (0.3-1.3)	0.7 (0.2-1.8)

Chi-square-test was used to compare the frequencies of genotypes between DM and control groups. \*Conditional logistic regression model adjustment for sex and age; †Conditional logistic regression model adjustment for sex, age, hypertension and metabolic syndrome; <sup>‡</sup> $P < 0.05$  compared to control group; <sup>§</sup> $P < 0.05$ . DM=Diabetes mellitus; OR=Odds ratio; CI=Confidence interval; vWF= von Willebrand factor; ADAMTS13=A disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13

were considered. The significant differences were found in frequencies of E and G alleles of the Q448E and rs2073932 in DM with multi-vessel disease and high Gensini score when compared to controls ( $P < 0.05$ ). However, there were no significant differences of other genotypes in those with single-vessel disease when compared to controls [Table 3]. Furthermore, multivariate logistic regression analysis was performed to investigate the relationship between *ADAMTS13* and *vWF* polymorphisms with severity of coronary stenosis. The results demonstrated that after adjustment for sex and age, the E allele carrier of the Q448E and the AA genotype of the rs652600 were significantly associated with an increased risk of multi-vessel disease (odds ratio [OR] [95% confidence interval (CI)] = 2.2 [1.0, 4.8],  $P = 0.047$  and 3.2 [1.0, 10.0],  $P = 0.043$ , respectively) [Figure 1a]. In addition, this study also revealed the significant association between the minor allele carrier of the Q448E and rs2073932 with high Gensini score when compared to the control group (OR [95% CI] = 2.3 [1.1, 4.9],  $P = 0.035$  and 2.3 [1.1, 5.1],  $P = 0.033$ , respectively) [Figure 1b].

*vWF* activity was significantly increased in the EE and GG genotypes of *ADAMTS13* Q448E and

rs2073932 when compared to heterozygous and wild type ( $P < 0.05$  and  $P < 0.01$ , respectively) as shown in Table 4. However, no association was found between *ADAMTS13* polymorphisms with *ADAMTS13* activity, except *vWF* V1565L ( $P < 0.01$ ) [Table 4]. According to the association of *ADAMTS13* polymorphisms and DM risk, additional assessment of the relationship between those polymorphisms and other biochemical parameters such as FBG, insulin, and HOMA-IR was performed. The results demonstrated that patients carrying the E, G, and A alleles of the Q448E, rs2073932, and rs652600 had significantly elevated FBS and HOMA-IR [Table 4], when compared to individuals carrying wild-type genotype. Furthermore, the result also showed a negative correlation between *ADAMTS13* activity and FBG in individuals carrying the EE and GG genotype of the Q448E and rs2073932 ( $r = -0.567$ ,  $P = 0.022$  and  $r = -0.712$ ,  $P = 0.001$ , respectively).

## DISCUSSION

The present study evaluated whether *ADAMTS13* and *vWF* levels were associated with type 2 DM and severity of coronary stenosis through the determination

**Table 3: Prevalence of a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13 and von Willebrand factor polymorphisms in diabetes mellitus patients with coronary artery disease according to number of stenotic vessels and Gensini score**

Polymorphism	Genotype frequency				
	Control (n=84)	DM with CAD			Gensini score
		Number of stenotic vessels		High score (n=46), n (%)	
		MVD (n=44), n (%)	SVD (n=18), n (%)		
<i>ADAMTS13</i> gene					
Q448E					
QQ	43 (51.2)	14 (31.8)	8 (44.4)	14 (30.4)	8 (50.0)
QE	34 (40.5)	24 (54.5)	7 (38.9)	26 (56.5)	5 (31.3)
EE	7 (8.3)	6 (13.6)	3 (16.7)	6 (13.0)	3 (18.8)
E allele	41 (48.8)	30 (68.2)*	10 (55.6)	32 (69.6)*	8 (50.0)
rs2073932					
AA	41 (48.8)	14 (31.8)	7 (38.9)	13 (28.3)	8 (50.0)
AG	34 (40.5)	24 (54.5)	7 (38.9)	26 (56.5)	5 (31.3)
GG	9 (10.7)	6 (13.6)	4 (22.2)	7 (15.2)	3 (18.8)
G allele	43 (51.2)	30 (68.2)*	11 (61.6)	33 (71.7)*	8 (50.0)
rs652600					
GG	37 (44.0)	13 (29.5)	7 (38.9)	13 (28.3)	7 (43.8)
GA	37 (44.0)	21 (47.7)	8 (44.4)	24 (52.2)	5 (31.3)
AA	10 (11.9)	10 (22.7)	3 (16.7)	9 (19.5)	4 (25.0)
A allele	47 (56.0)	31 (70.5)	11 (61.1)	31 (71.7)	9 (56.2)
rs4962153					
GG	65 (77.4)	36 (81.8)	14 (77.8)	38 (82.6)	12 (75.0)
GA	15 (17.9)	8 (18.2)	3 (16.7)	8 (17.4)	3 (18.8)
AA	4 (4.8)	0	1 (5.6)	0	1 (6.3)
A allele	19 (22.6)	8 (18.2)	4 (22.2)	8 (17.4)	4 (25.0)
<i>vWF</i> gene					
V1565L					
VV	67 (79.8)	38 (88.4)	17 (94.4)	40 (88.9)	15 (93.8)
VL	17 (20.2)	5 (11.6)	1 (5.6)	5 (11.1)	1 (6.3)

Chi-square test was performed for comparison of frequencies of each genotype among the study groups. \* $P < 0.05$  compared to control group. DM=Diabetes mellitus; CAD=Coronary artery disease; MVD=Multi vessel disease; SVD=Single vessel disease; vWF=von Willebrand factor; ADAMTS13=A disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13

of ADAMTS13 activity, vWF antigen, and activity along with their polymorphisms in DM and control individuals. The results demonstrated that vWF antigen was likely to increase in DM when compared to the controls which was consistent with the previous studies.<sup>[8,9]</sup> Moreover, this is the first investigation of the relationship between ADAMTS13 polymorphisms and type 2 DM in Thai population. The results showed that minor E and G alleles of ADAMTS13 Q448E and rs2073932 and the AA genotype of rs652600 polymorphisms were independently associated with type 2 DM in this population. However, the mechanism that links genetic variations of ADAMTS13 to risk of DM is remained unclear. To date, many genome-wide association studies have investigated the novel genetic susceptibility to type 2 DM. Previous studies found that the rs10811661 of cyclin-dependent kinase inhibitor 2A/B (*CDKN2A/B*) gene was associated with impaired insulin secretion and type 2 DM.<sup>[23]</sup> As *CDKN2A/B* gene (9p21.3) is located near ADAMTS13 gene (9q34), it is possible that ADAMTS13 polymorphisms may be in linkage disequilibrium with this polymorphism. Other explanations may be explored

from the results of this study showing the association of the minor alleles of ADAMTS13 Q448E, rs2073932, and rs652600 with increase in FBG and HOMA-IR, which may indicate the hyperglycemic condition, and the negative correlation of ADAMTS13 activity with FBG in individuals possessing the minor alleles of those polymorphisms. Taking this into account, this may in part contribute to the association of ADAMTS13 polymorphisms with DM.

An elevated vWF antigen in diabetic patients is associated with increased risk of thrombosis and cardiovascular events. In addition, the imbalance between vWF and ADAMTS13 levels was associated with promoting the atherosclerosis progression by increasing leukocyte rolling and adhesion.<sup>[24]</sup> Therefore, alterations of ADAMTS13 and vWF levels by ADAMTS13 polymorphisms may partly contribute to atherosclerosis in type 2 DM. So far, however, no study has examined the possible role of the ADAMTS13 polymorphisms with atherosclerotic lesion progression in type 2 DM. This present study demonstrated that individuals carrying the minor E and G alleles of Q448E

**Table 4: Association of genetic variations with von Willebrand factor activity and antigen, a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13 activity, and von Willebrand factor antigen/a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13 ratio**

Polymorphism	Parameters						
	vWF activity (IU/dL)	vWF antigen (IU/dL)	ADAMTS13 activity (%)	vWF/ADAMTS13 ratio	FBG (mmol/L)	Insulin (µIU/mL)	HOMA-IR
<i>ADAMTS13</i> gene							
Q448E							
QQ (n=72)	97.2±21.2*	83.8±37.3	71.8±18.2	1.3±1.0	6.1±2.5*,†	16.6±1.8	4.3±2.1*
QE (n=79)	92.9±29.3†	91.8±42.8	78.0±17.5	1.2±0.6	7.2±3.4	17.8±1.7	5.4±2.0
EE (n=20)	114.0±33.4*,†	95.7±40.6	76.0±17.7	1.4±0.8	8.5±4.2*	16.2±1.5	5.9±2.0
E allele (n=99)	97.2±31.2	92.6±42.2	77.6±17.5	1.3±0.6	7.5±3.6†	17.4±1.7	5.5±2.0*
rs2073932							
AA (n=68)	97.6±21.5†	85.5±37.2	71.0±18.4	1.4±1.0	6.1±2.5*,†	15.8±1.6	4.2±1.9*
AG (n=81)	93.0±29.3*	91.2±42.9	77.6±17.5	1.2±0.6	7.2±3.4	20.0±1.6	5.5±2.0
GG (n=22)	111.0±32.3*,†	91.0±41.0	79.1±16.8	1.2±0.7	8.2±4.1*	15.8±2.0	5.9±2.7
G allele (n=103)	96.9±30.7	91.2±42.3	77.9±17.3	1.2±0.6	7.4±3.5†	17.8±1.8	5.5±2.1*
rs652600							
GG (n=63)	95.7±21.6	85.4±38.7	71.5±18.6*	1.4±1.0	6.1±2.6*,†	15.8±2.0	4.3±2.1‡
GA (n=80)	95.5±28.8	88.9±40.4	77.2±18.0	1.2±0.6	7.2±3.6	17.8±1.6	5.4±2.1
AA (n=28)	105.2±33.8	96.9±43.9	77.7±15.6	1.3±0.7	7.8±2.9*	15.1±1.6	5.2±1.7
A allele (n=108)	98.0±30.3	90.9±41.3	77.3±17.3*	1.2±0.6	7.4±3.4†	17.0±1.7	5.4±2.0‡
rs4962153							
GG (n=133)	96.2±27.7	85.4±41.2*	75.9±18.0	1.2±0.9	6.9±3.1	15.8±1.7	4.9±2.0
GA (n=33)	99.9±26.2	102.2±34.7	73.2±17.3	1.5±0.6	6.9±3.7	17.0±2.0	4.8±2.4
AA (n=5)	104.8±30.0	94.0±41.2	70.3±22.4	1.5±0.6	6.2±2.0	20.4±1.2	5.5±1.4
A allele (n=38)	100.5±26.4	101.1±35.1*	72.8±17.7	1.5±0.6	6.8±3.5	17.4±1.9	4.9±2.3
vWF V1565L							
VV (n=141)	97.0±26.8	89.0±41.0	73.4±18.2†	1.3±0.9	7.0±3.3	17.4±1.7	5.1±2.1
VL (n=28)	98.3±31.3	91.6±36.7	82.9±14.7†	1.2±0.5	6.3±2.5	16.6±1.7	4.5±2.0

One-way ANOVA was performed to compare continuous values among genotypes. Values in parentheses represent number of subjects. Values of FBG, insulin and HOMA-IR are presented as geometric mean±SD. \*, †P<0.05 and <0.01; ‡P for trend=0.041. FBG=Fasting blood glucose; HOMA-IR=Homeostasis model assessment of insulin resistance; ANOVA=Analysis of variance; SD=Standard deviation; vWF= von Willebrand factor; ADAMTS13=A disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13

and rs2073932 as well as the AA genotype of rs652600 were associated with increased risk of multi-vessel disease and high Gensini score. These results suggested that *ADAMTS13* polymorphisms may affect the occurrence and progression of vascular lesion in type 2 DM. Based on this finding, they may reduce ADAMTS13 activity or increase vWF antigen and/or activity. This study revealed the relationship of homozygous variants of Q448E and rs2073932 with increased vWF activity which was consistent with our previous study.<sup>[14]</sup> To date, some studies have shown that vWF was positively correlated with Gensini score<sup>[25]</sup> and vascular endothelial growth factor,<sup>[26]</sup> which associated with increased atherosclerosis progression.<sup>[27]</sup> Therefore, the association between *ADAMTS13* polymorphisms and vWF activity may in turn support their roles in promoting atherosclerosis progression in type 2 DM individuals. However, it should be noted that the sample size in this study was relatively small especially in each subgroup which may reduce the statistical power of tests. Thus, further investigation with a larger sample size is needed to elucidate the exact mechanism and association of *ADAMTS13* polymorphisms with type 2 DM.

## CONCLUSION


The present study has demonstrated the association of *ADAMTS13* polymorphisms with type 2 DM and severity of coronary stenosis. These relationships suggested the importance of genetic variations of *ADAMTS13* which may eventually be used as the atherosclerotic risk assessment in diabetic individuals.

## Acknowledgments

This study and Lasom S. were supported by the grant from the National Research University, Office of the Higher Education Commission, Ministry of Education Thailand, the National Research Council of Thailand, and the Cardiovascular Research Group, Khon Kean University.

## Financial support and sponsorship

This manuscript and Lasom S. were supported by the grant from the National Research University, Office of the Higher Education Commission, Ministry of Education Thailand, the National Research Council of Thailand, and the Cardiovascular Research Group, Khon Kean University.



**Figure 1:** Adjusted odds ratio for predicting severity of coronary stenosis in diabetes mellitus with each genotype of the polymorphisms. Odds ratios represent risk of coronary stenosis according to number of vessel stenosis (a) and Gensini score (b) in diabetes mellitus individuals with coronary artery disease compared to controls. The vertical bars represent 95% confident interval. The horizontal dashed line indicates the reference value (odds ratios = 1.0). \* $P < 0.05$

### Conflicts of interest

There are no conflicts of interest.

### REFERENCES

- Bonow RO, Gheorghiadu M. The diabetes epidemic: A national and global crisis. *Am J Med* 2004;116 Suppl 5A:2S-10S.
- Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, *et al.* Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). *Eur Heart J* 2007;28:88-136.
- Jin C, Lu L, Zhang RY, Zhang Q, Ding FH, Chen QJ, *et al.* Association of serum glycated albumin, C-reactive protein and ICAM-1 levels with diffuse coronary artery disease in patients with type 2 diabetes mellitus. *Clin Chim Acta* 2009;408:45-9.
- Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. *Blood* 2008;112:11-8.
- Sonneveld MA, de Maat MP, Portegies ML, Kavousi M, Hofman A, Turecek PL, *et al.* Low ADAMTS13 activity is associated with an increased risk of ischemic stroke. *Blood* 2015;126:2739-46.
- Matsukawa M, Kaikita K, Soejima K, Fuchigami S, Nakamura Y, Honda T, *et al.* Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction. *Am J Cardiol* 2007;100:758-63.
- Miura M, Kaikita K, Matsukawa M, Soejima K, Fuchigami S, Miyazaki Y, *et al.* Prognostic value of plasma von willebrand factor-cleaving protease (ADAMTS13) antigen levels in patients with coronary artery disease. *Thromb Haemost* 2010;103:623-9.
- Skeppholm M, Kallner A, Kalani M, Jörneskog G, Blombäck M, Wallén HN, *et al.* ADAMTS13 and von willebrand factor concentrations in patients with diabetes mellitus. *Blood Coagul Fibrinolysis* 2009;20:619-26.
- Verkleij CJ, Bruijn RE, Meesters EW, Gerdes VE, Meijers JC, Marx PF, *et al.* The hemostatic system in patients with type 2 diabetes with and without cardiovascular disease. *Clin Appl Thromb Hemost* 2011;17:E57-63.
- Domingueti CP, Fuzatto JA, Fóscolo RB, Reis JS, Dusse LM, Carvalho MD, *et al.* Association between von willebrand factor, disintegrin and metalloproteinase with thrombospondin type 1 motif member 13, d-dimer and cystatin C levels with retinopathy in type 1 diabetes mellitus. *Clin Chim Acta* 2016;459:1-4.
- Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH, *et al.* Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: Progressive, interrelated, and independently associated with risk of death. *Diabetes* 2002;51:1157-65.
- Rurali E, Noris M, Chianca A, Donadelli R, Banterla F, Galbusera M, *et al.* ADAMTS13 predicts renal and cardiovascular events in type 2 diabetic patients and response to therapy. *Diabetes* 2013;62:3599-609.
- Plaimauer B, Fuhrmann J, Mohr G, Wernhart W, Bruno K, Ferrari S, *et al.* Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation. *Blood* 2006;107:118-25.
- Lasom S, Komanasin N, Settatsian N, Settatsian C, Kukongviriyapan U, Intharapetch P, *et al.* Protective effect of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 haplotype on coronary artery disease. *Blood Coagul Fibrinolysis* 2017;28:286-94.
- Kraisin S, Palasuwan A, Popruk S, Nantakomol D. Reduced ADAMTS13 activity is associated with an ADAMTS13 SNP, fever and microparticles in a malaria-like model. *Malar J* 2014;13:3.
- World Health Organization. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation. Geneva: The WHO Document Production Services; 2006.
- Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. *Am J Cardiol* 1983;51:606.
- Chen ZW, Chen YH, Qian JY, Ma JY, Ge JB. Validation of a novel clinical prediction score for severe coronary artery diseases before elective coronary angiography. *PLoS One* 2014;9:e94493.
- National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III) final report. *Circulation* 2002;106:3143-421.
- Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. *J Hypertens* 2003;21:1983-92.
- World Health Organization. Refining Obesity and its Treatment. The Asia-Pacific Perspective. Sydney: Health Communications Australia; 2000.
- Suriyaprom K, Phonrat B, Tungtrongchitr R. Association of adiponectin gene -11377C>G polymorphism with adiponectin

- levels and the metabolic syndrome in Thais. *Asia Pac J Clin Nutr* 2014;23:167-73.
23. Wen J, Rönn T, Olsson A, Yang Z, Lu B, Du Y, *et al.* Investigation of type 2 diabetes risk alleles support CDKN2A/B, CDKAL1, and TCF7L2 as susceptibility genes in a han Chinese cohort. *PLoS One* 2010;5:e9153.
  24. Gandhi C, Khan MM, Lentz SR, Chauhan AK. ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice. *Blood* 2012;119:2385-91.
  25. Li Q, Zhang Z, Du R, Hu X, Yan Y, Gao Q, *et al.* Association analysis between endothelial function related factors and coronary artery stenosis degree in coronary heart disease patients with type 2 diabetes mellitus. *J Pediatr Endocrinol Metab* 2012;25:711-6.
  26. Shao Y, Lv C, Yuan Q, Wang Q. Levels of serum 25(OH) VD3, HIF-1, VEGF, vWf, and IGF-1 and their correlation in type 2 diabetes patients with different urine albumin creatinine ratio. *J Diabetes Res* 2016;2016:1925424.
  27. Heinonen SE, Kivelä AM, Huusko J, Dijkstra MH, Gurzeler E, Mäkinen PI, *et al.* The effects of VEGF-A on atherosclerosis, lipoprotein profile, and lipoprotein lipase in hyperlipidaemic mouse models. *Cardiovasc Res* 2013;99:716-23.

